Xspray Pharma
Develops improved cancer drugs (PKIs) using a patented amorphous formulation technology.
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Manufacturing
Description
Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-06 07:30 |
Xspray resolves on a rights issue of approximately SEK 135 million and raises a…
|
English | 79.3 KB | ||
| 2024-10-21 15:20 |
Xspray Pharmas valberedning inför årsstämman 2025
|
Swedish | 44.7 KB | ||
| 2024-08-07 08:02 | Swedish | 715.8 KB | |||
| 2024-08-07 08:00 | English | 710.5 KB | |||
| 2024-07-26 21:20 |
Xspray Pharma lämnar ny information om Dasynoc, en ny behandling för KML under …
|
Swedish | 46.7 KB | ||
| 2024-07-26 21:20 |
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Devel…
|
English | 45.3 KB | ||
| 2024-07-09 17:15 |
Xspray Pharmas studie på XS003 visar matchande biotillgänglighet vid mer än 50%…
|
Swedish | 46.0 KB | ||
| 2024-07-09 17:15 |
Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more t…
|
English | 45.1 KB | ||
| 2024-05-31 17:30 |
New number of shares and votes in Xspray Pharma after TO6
|
English | 41.0 KB | ||
| 2024-05-31 17:30 |
Nytt antal aktier och röster i Xspray Pharma efter TO6
|
Swedish | 42.5 KB | ||
| 2024-05-21 10:55 |
Kommuniké från årsstämma i Xspray Pharma AB (publ) 21 maj 2024
|
Swedish | 45.7 KB | ||
| 2024-05-21 10:55 |
Bulletin from the annual general meeting of Xspray Pharma AB (publ), 21 May 2024
|
English | 44.5 KB | ||
| 2024-05-20 17:45 |
Xspray Pharma utser Chief Operating Officer och ändrar i ledningsgruppen
|
Swedish | 44.5 KB | ||
| 2024-05-20 17:45 |
Xspray Pharma appoints Chief Operating Officer and changes the Management Team
|
English | 43.3 KB | ||
| 2024-05-08 08:00 | Swedish | 1.4 MB |
Automate Your Workflow. Get a real-time feed of all Xspray Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xspray Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xspray Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Anders Ekblom | Other | Buy | 168,000 | 4,998,000.00 SEK |
| 2024-06-04 | Ribbskottet AB Anders Bladh | Other | Buy | 1,958 | 145,655.62 SEK |
| 2024-06-03 | Anders Bladh, Ribbskottet | Other | Buy | 3,042 | 225,077.58 SEK |
| 2024-05-29 | Per Andersson | Other | Buy | 51,749 | 489,545.54 SEK |
| 2024-05-27 | Per Andersson | Other | Sell | 9,950 | 687,545.00 SEK |
| 2024-05-16 | Anders Bladh | Other | Buy | 10,000 | 503,500.00 SEK |
| 2024-05-02 | Maris Hartmanis | Other | Other | 2,385 | 95,400.00 SEK |
| 2024-05-02 | Christine Lind | Other | Other | 666 | 26,640.00 SEK |
| 2024-05-02 | Anders Ekblom | Other | Other | 500 | 20,000.00 SEK |
| 2024-03-05 | Robert Molander | Other | Buy | 5,000 | 20,000.00 USD |
Peer Companies
